Price
No data yet.
Social Signal Score
Analyst Ratings
37 analystsRevenue
$210.88M+422.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wael Mohamed
- Sector
- Technology
- Industry
- Software - Infrastructure
- Employees
- 2,613
- Beta
- 1.01
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.06
Financials
Revenue
$210.88M+422.8%Net Income
$6.07MEBITDA
$19.63MFree Cash Flow
$35.83M+10925.8%EPS (diluted)
$0.09Shares Outstanding (diluted)
67.92M+63.7%Operating Expenses
$140.64MCash & Debt
$702.58MReturn of Capital
$47.0KRevenue by Segment (annual)
$859.79MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $859.79M | $23.38M | $0.36 |
| 2024 | $844.01M | $25.53M | $0.41 |
| 2023 | $777.71M | $-149.26M | $-2.46 |
| 2022 | $685.08M | $-124.72M | $-2.13 |
| 2021 | $535.40M | $-146.33M | $-2.65 |
| 2020 | $411.49M | $-98.85M | $-1.94 |
| 2019 | $326.95M | $-53.84M | $-1.10 |
| 2018 | $244.09M | $-55.55M | $-1.20 |
| 2017 | $200.94M | $-45.47M | $-1.06 |
| 2016 | $157.44M | $-49.00M | $-1.19 |
| 2015 | $110.53M | $-49.86M | $-2.02 |
| 2014 | $76.88M | $-32.63M | $-1.05 |
| 2013 | $60.03M | $-18.87M | $-0.61 |
| 2012 | $46.04M | $-12.39M | $-0.46 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.53
- Implied price
- $22.29
- Return from $12.44
- 12.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $11.08 — -10.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 30 | 36 | 42 | 48 | 54 |
|---|---|---|---|---|---|
| -2.0% | -4.7% | -1.1% | 2.0% | 4.7% | 7.2% |
| 3.0% | 0.2% | 3.9% | 7.2% | 10.1% | 12.7% |
| 8.0% | 5.1% | 9.0% | 12.4% | 15.4% | 18.2% |
| 13.0% | 9.9% | 14.0% | 17.6% | 20.8% | 23.6% |
| 18.0% | 14.8% | 19.1% | 22.8% | 26.1% | 29.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
55-64.52%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·4d ago·Neutral
Rapid7 Launches Rapid7 Intelligence to Harness Threat Data Against Attackers BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today, Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, announced the launch of Rapid7 Intelligence, a unified engine designed to transform enterprise threat defenses from reactive monitoring to proactive prevention. By combining threat intelligence, vulnerability research, and the legacy of Rapid7 Labs, Rapid7 Intelligence transforms i…
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Rapid7, Inc. (RPD) Presents at Citi's 2026 Global TMT Conference Transcript Rapid7, Inc. (RPD) Presents at Citi's 2026 Global TMT Conference Transcript
View source ↗ - Newsglobenewswire.com·27d ago·Negative
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric …
View source ↗ - Newsglobenewswire.com·28d ago·Negative
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peel…
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Rapid7 to Participate in Upcoming Investor Conferences BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today announced that the company will be attending the following conferences:
View source ↗ - Newsgurufocus.com·33d ago·Neutral
Rapid7 Inc (RPD) Shares Fall 7.8% -- What GF Score of 54 Tells Investors On September 02, 2026, Rapid7 Inc (RPD) shares fell 7.8% to $11.07, marking a significant decline in an already challenging year. The stock has fluctuated betwe
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Rapid7: Q2 Beat Validates The Bull Case Rapid7 remains a 'Buy,' considering the positive read-throughs from its recent quarterly disclosures. RPD's 2Q2026 EPS came in 26% above consensus, as the EBIT margin expanded sequentially by 200bps to 13.7%. The second-quarter beat aligns with my belief that RPD is benefiting from AI-linked demand and cost-cutting under new leadership.
View source ↗ - Newsglobenewswire.com·49d ago·Negative
…ds Nearly Two-Thirds of Vulnerabilities Exploited in Q2 2026 Required No User Interaction to Initiate BOSTON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today released its Quarterly Threat Landscape Report , revealing that rising vulnerability volumes and faster weaponization are breaking traditional patching models. The findings reinforce that security teams must move beyond static severity scores and prioritize …
View source ↗ - Newsmarketbeat.com·56d ago·Negative
Rapid7 Q2 Earnings Call Highlights Rapid7 NASDAQ: RPD reported second-quarter fiscal 2026 results that exceeded its guided metrics, while outlining a restructuring and strategic reset centered on Detection and Response, Exposure Management and artificial intelligence-driven platform capabilities.
View source ↗ - Newszacks.com·56d ago·Neutral
Rapid7 (RPD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Rapid7 (RPD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Rapid7, Inc. (RPD) Q2 2026 Earnings Call Transcript Rapid7, Inc. (RPD) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·56d ago·Positive
Rapid7 (RPD) Q2 Earnings and Revenues Top Estimates Rapid7 (RPD) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.58 per share a year ago.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.46 per share
Typical surprise +26.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$0.44 vs $0.35beat
- Tue, May 5$0.36 vs $0.30beat
- Tue, Feb 10$0.44 vs $0.40beat
- Tue, Nov 4$0.57 vs $0.45beat
- Thu, Aug 7$0.58 vs $0.44beat
- Mon, May 12$0.49 vs $0.35beat
Estimates and results for RPD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RPD officers and directors.
- Bought
- $19.0m
- Sold
- $1.1m
10 trades
11 trades
- Murphy Scott Msold
- Murphy Scott Msold
- Murphy Scott Msold
- Jana Partners Management, Lpbought
- Schodorf Thomas Ebought
- Brown Marc Evanbought
- Jana Partners Management, Lpbought
- Murphy Scott Msold
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Buy$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (14d later)Buy$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Mar 9, 2025 (13d later)Sell$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 8, 2024 (24d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2020 (21d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 16, 2020 (37d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Mar 16, 2020 (31d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2020 (18d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.